Atea Pharmaceuticals AVIR
NASDAQ AVIR
$4.05 -0.03 (-0.74%)
At close: Oct 22, 2026 · 4:00 PM EDT

Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021)

Updated

Atea Pharmaceuticals' Current Deferred Revenue came in at $192.18 million for Q3 2021, down 14.6% from the prior quarter.

Analysis

Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021) Analysis & Trends

At the end of FY2020, Atea Pharmaceuticals' Current Deferred Revenue was $301.37 million.

  • Business Quant data shows AVIR's Current Deferred Revenue at $224.99 million (Q2 2021), $235.38 million (Q1 2021) and $301.37 million (Q4 2020) in the three quarters before Q3 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 Atea Pharmaceuticals 325.17 Mn -781.44 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 192.18 Mn
Jun 30, 2021 224.99 Mn
Mar 31, 2021 235.38 Mn
Dec 31, 2020 301.37 Mn
API Access

Atea Pharmaceuticals Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=AVIR&period=max&api_key=YOUR_API_KEY